Skip to main content
See every side of every news story
Published • loading... • Updated

Merck’s drug prolongs survival in advanced stomach, esophageal cancers in trial

Summary by WTVB
Nov 20 (Reuters) - Merck said on Friday that its experimental cancer drug helped patients with advanced stomach and esophageal ​cancers live longer than standard treatment ‌options in a late-stage trial. Here are some details: • The trial compared the ...

9 Articles

Right

New Med Prolongs Stomach, Esophageal Cancer Survival

·Boca Raton, United States
Read Full Article

The clinical trial compared Merck's drug sacituzumab tirumotecan, also known as sac-TMT, with doctor-chosen chemotherapy, such as trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources lean Right
75% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

WTVB broke the news on Friday, November 20, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal